The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...
HISTORIC LAUNCH TO LOWER DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced an expansion of TrumpRx.gov to provide unprecedented price transparency and choice on generic ...
Lupin is increasing its focus on complex generics, specialty medicines and differentiated products as global patent expiries create opportunities in regulated markets. The company reported growth in ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Eli Lilly's market share in India's weight‑loss drug market fell to 56% in March from 61% in February. Novo Nordisk's market share remained steady at 25%. Indian generic drugmakers have launched 26 ...
The last time I wrote on Novo Nordisk (NVO), it was with a Seeking Alpha article entitled "Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback." With respect to this article, I ...
1. The Secretary of Commerce (Secretary) recently transmitted to me a report on his investigation into the effects of imports of pharmaceuticals and pharmaceutical ingredients on the national security ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results